Employees: 1,180
Size COLTENE (CLTN.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $339M, the 151st largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 47.80 on 18 Nov 2026.
Performance Over six months the shares fell 7.0%, against -15.3% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 9th highest of 20 in its peer set.
Growth Revenue fell 2.5% over the last twelve months (peer median +7.0%); the operating margin is 7.9% (peer median 9.4%).
Valuation It trades at 25.2× forward earnings against a peer median of 17.5× (4th most expensive of 12).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 6.7 points above its cost of capital (5.0% WACC).
Next results Next results expected around 5 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 235M | CHF 240M | CHF 250M | CHF 243M | CHF 267M |
| Revenue growth | — | -4% | +3% | -9% | — |
| Gross profit | CHF 58.9M | CHF 61.5M | CHF 67.7M | CHF 59.7M | CHF 78.3M |
| EBITDA | CHF 26.0M | CHF 27.7M | CHF 33.7M | CHF 26.6M | CHF 41.7M |
| Net income | CHF 14.7M | CHF 14.9M | CHF 20.5M | CHF 11.9M | CHF 26.0M |
| Free cash flow | CHF 14.5M | CHF 9.17M | CHF 23.8M | CHF 19.1M | CHF 17.9M |
| Capital expenditure | CHF 6.63M | CHF 6.08M | CHF 5.75M | CHF 8.68M | CHF 8.32M |
| Total debt | n/a | CHF 47.0M | CHF 40.0M | CHF 45.0M | CHF 47.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CLTN.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.4% | -9.8% | 5th highest of 21 |
| 6-month return | -7.0% | -15.3% | 9th highest of 20 |
| Distance from 52-week high | -19.0% | -45.3% | 4th highest of 21 |
| Revenue growth (TTM) | -2.5% | +7.0% | 9th lowest of 21 |
| Operating margin | 7.9% | 9.4% | 10th lowest of 21 |
| Forward P/E | 25.2× | 17.5× | 4th most expensive of 12 |
| Growth the price implies (Req g, 7 yrs) | -0.3% | 15.8% | 7th least demanding of 16 |
| Growth delivered (Del g) | -0.7% | +0.4% | 6th lowest of 16 |
| Hurdle (Req g minus delivered) | +0.4 pp | +6.1 pp | 6th least demanding of 16 |
| ROIC minus cost of capital | +6.7 pp | +0.6 pp | 9th highest of 19 |
| EV / EBITDA | 12.3× | 8.3× | 4th most expensive of 11 |
| Net debt / EBITDA | 1.3× | -2.1× | 5th most indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| COLTENE CLTN.SW | Switzerland | $339M | -7% | -2% | 8% | 25.2× | -0.3% | -0.7% |
| Nanjing Medlander Medical Technology 688273.SS | China | $337M | -47% | -12% | 8% | 17.5× | 35.3% | +5.2% |
| BioNote 377740.KS | South Korea | $337M | -14% | +12% | 18% | 14.4× | -15.0% | -28.5% |
| Jiangsu Huayang Intelligent Equipment 301502.SZ | China | $336M | -36% | -5% | 2% | n/a | 34.3% | +0.4% |
| YD Bio YDES | United States | $344M | +7% | +17% | -883% | n/a | n/a | n/a |
| Embecta EMBC | United States | $345M | +99% | -8% | 26% | 3.8× | -19.9% | -0.1% |
| Tauns Laboratories 197A.T | Japan | $327M | -3% | +7% | 29% | 16.7× | n/a | n/a |
| Chemclin Diagnostics 688468.SS | China | $327M | -24% | -10% | 4% | n/a | 15.8% | -4.5% |
| Jiangsu Apon Medical Technology 300753.SZ | China | $326M | -34% | -15% | -10% | 862.0× | 20.0% | -5.1% |
| IVF HARTMANN VBSN.SW | Switzerland | $352M | -2% | +7% | 14% | n/a | -12.7% | -1.3% |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $326M | -27% | +12% | -2% | n/a | n/a | n/a |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $354M | -23% | -8% | 17% | 36.0× | 18.4% | +4.4% |
| Japan Eyewear 5889.T | Japan | $318M | -5% | +15% | 32% | 10.7× | -9.4% | +20.2% |
| Beijing Succeeder Technology 688338.SS | China | $362M | -18% | -4% | 31% | 16.4× | 5.7% | +3.4% |
| Star Sports Medicine 1609.HK | Hong Kong | $364M | -73% | +23% | 37% | n/a | -13.1% | +36.8% |
| Stratec SBS.DE | Germany | $365M | +63% | -6% | 4% | 18.2× | 19.1% | +0.1% |
| CapsoVision CV | United States | $366M | +5% | +15% | -213% | n/a | n/a | n/a |
| Brainsway Ltd Sponsored ADR BWAY | United States | $373M | -41% | +32% | 14% | 20.3× | 24.9% | +18.8% |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $373M | -15% | +7% | 11% | 25.3× | -4.2% | -6.0% |
| ACRO Biomedical 6748.TWO | Taiwan | $377M | +158% | +45% | -178% | n/a | n/a | n/a |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $378M | n/a | +19% | 2% | n/a | 17.1% | +18.1% |